Literature DB >> 24696608

Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity?

Takahiro Nakazawa1, Itaru Naitoh1, Kazuki Hayashi1, Hitoshi Sano1, Katsuyuki Miyabe1, Shuya Shimizu1, Takashi Joh1.   

Abstract

This is a review of the characteristic findings of inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) and their usefulness in the diagnosis of sclerosing cholangitis. PSC is a chronic inflammatory disease characterized by idiopathic fibrous obstruction and is frequently associated with IBD. IBD-associated with PSC (PSC-IBD) shows an increased incidence of pancolitis, mild symptoms, and colorectal malignancy. Although an increased incidence of pancolitis is a characteristic finding, some cases are endoscopically diagnosed as right-sided ulcerative colitis. Pathological studies have revealed that inflammation occurs more frequently in the right colon than the left colon. The frequency of rectal sparing and backwash ileitis should be investigated in a future study based on the same definition. The cholangiographic findings of immunoglobulin G4-related sclerosing cholangitis (IgG4-SC) are similar to those of PSC. The rare association between IBD and IgG4-SC and the unique characteristics of PSC-IBD are useful findings for distinguishing PSC from IgG4-SC.

Entities:  

Keywords:  Immunoglobulin G4-related sclerosing cholangitis; Inflammatory bowel disease; Inflammatory bowel disease-associated with primary sclerosing cholangitis; Primary sclerosing cholangitis

Mesh:

Substances:

Year:  2014        PMID: 24696608      PMCID: PMC3964396          DOI: 10.3748/wjg.v20.i12.3245

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  44 in total

1.  Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis.

Authors:  Erin W Thackeray; Phunchai Charatcharoenwitthaya; Diaa Elfaki; Emmanouil Sinakos; Keith D Lindor
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-01       Impact factor: 11.382

2.  Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  Hitoshi Sano; Takahiro Nakazawa; Tomoaki Ando; Kazuki Hayashi; Itaru Naitoh; Fumihiro Okumura; Katsuyuki Miyabe; Michihiro Yoshida; Satoru Takahashi; Hirotaka Ohara; Takashi Joh
Journal:  J Hepatobiliary Pancreat Sci       Date:  2011-03       Impact factor: 7.027

3.  High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors:  H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

4.  Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis.

Authors:  J R Cangemi; R H Wiesner; S J Beaver; J Ludwig; R L MacCarty; R R Dozois; A R Zinsmeister; N F LaRusso
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

5.  Primary sclerosing cholangitis in Japan--analysis of 192 cases.

Authors:  H Takikawa; T Manabe
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

6.  Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: a Japanese cohort.

Authors:  Hirotaka Ohara; Takahiro Nakazawa; Shigeyuki Kawa; Terumi Kamisawa; Tooru Shimosegawa; Kazushige Uchida; Kenji Hirano; Takayoshi Nishino; Hideaki Hamano; Atsushi Kanno; Kenji Notohara; Osamu Hasebe; Takashi Muraki; Etsuji Ishida; Itaru Naitoh; Kazuichi Okazaki
Journal:  J Gastroenterol Hepatol       Date:  2013-07       Impact factor: 4.029

7.  Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Hirotaka Ohara; Hitoshi Sano; Shigeru Aoki; Shinya Kobayashi; Tetsu Okamoto; Hideto Imai; Tomoyuki Nomura; Takashi Joh; Makoto Itoh
Journal:  Gastrointest Endosc       Date:  2004-12       Impact factor: 9.427

8.  IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis?

Authors:  Yoh Zen; Kenichi Harada; Motoko Sasaki; Yasunori Sato; Koichi Tsuneyama; Joji Haratake; Hiroshi Kurumaya; Kazuyoshi Katayanagi; Shinji Masuda; Hideki Niwa; Hideo Morimoto; Atsuo Miwa; Akio Uchiyama; Bernard C Portmann; Yasuni Nakanuma
Journal:  Am J Surg Pathol       Date:  2004-09       Impact factor: 6.394

Review 9.  Primary sclerosing cholangitis--what is the difference between east and west?

Authors:  Ali Shorbagi; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

10.  Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship.

Authors:  Emmanouil Sinakos; Sunil Samuel; Felicity Enders; Edward V Loftus; William J Sandborn; Keith D Lindor
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

View more
  15 in total

Review 1.  Adult bile duct strictures: differentiating benign biliary stenosis from cholangiocarcinoma.

Authors:  Hiep Nguyen Canh; Kenichi Harada
Journal:  Med Mol Morphol       Date:  2016-06-27       Impact factor: 2.309

2.  The 2016 diagnostic criteria for primary sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Kenji Notohara; Susumu Tazuma; Atsushi Tanaka; Hiroyuki Isayama; Toshio Tsuyuguchi; Toshiyuki Mori; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2016-12-05       Impact factor: 7.527

Review 3.  Gastrointestinal considerations related to youth sports and the young athlete.

Authors:  Garrett Koon; Orhan Atay; Sameer Lapsia
Journal:  Transl Pediatr       Date:  2017-07

4.  Clinical relevance of endoscopic peri-appendiceal red patch in ulcerative colitis patients.

Authors:  Maud A Reijntjes; Lianne Heuthorst; Krisztina Gecse; Aart Mookhoek; Willem A Bemelman; Christianne J Buskens
Journal:  Therap Adv Gastroenterol       Date:  2022-06-28       Impact factor: 4.802

5.  IgG4+ plasma cell infiltration is correlated with the development of inflammatory bowel disease and can be regulated by TLR-4.

Authors:  Xiaowei Chen; Wenwen Sun; Risheng Lin; Zhiming Huang; Weichang Chen
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

Review 6.  Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.

Authors:  Carolina Palmela; Farhad Peerani; Daniel Castaneda; Joana Torres; Steven H Itzkowitz
Journal:  Gut Liver       Date:  2018-01-15       Impact factor: 4.519

Review 7.  Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence.

Authors:  Andrew Mertz; Nhu An Nguyen; Konstantinos H Katsanos; Ryan M Kwok
Journal:  Ann Gastroenterol       Date:  2019-01-15

8.  [Surgical treatment of primary sclerosing cholangitis : Experiences from 30 years in a single center cohort with 173 consecutive patients].

Authors:  Vittorio Branchi; Tobias J Weismüller; Taotao Zhou; Jonas Henn; Alexander Semaan; Tim R Glowka; Maria Gonzalez-Carmona; Christian Strassburg; Jörg C Kalff; Steffen Manekeller; Hanno Matthaei
Journal:  Chirurg       Date:  2021-02       Impact factor: 0.955

Review 9.  Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Authors:  Fotios S Fousekis; Vasileios I Theopistos; Ioannis V Mitselos; Alexandros Skamnelos; Athanasios Kavvadias; Konstantinos H Katsanos; Dimitrios K Christodoulou
Journal:  J Clin Med Res       Date:  2019-01-05

10.  Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients.

Authors:  Juliana Silva; Beatriz S Brito; Isaac Neri de N Silva; Viviane G Nóbrega; Maria Carolina S M da Silva; Hemerson Dyego de N Gomes; Flora Maria Fortes; Andrea M Pimentel; Jaciane Mota; Neogélia Almeida; Valdiana C Surlo; André Lyra; Raquel Rocha; Genoile O Santana
Journal:  Biomed Res Int       Date:  2019-01-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.